← FDA DRUG APPROVALS

FDA NDA · NDA021285

TRILEPTAL

oxcarbazepine

Sponsor: NOVARTIS

APPLICATION
NDA021285
TYPE
NDA
ORIGINAL APPROVAL
2001-05-25
LATEST ACTION
2025-09-23
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

TRILEPTAL · ReferencePrescription
OXCARBAZEPINE 300MG/5ML · SUSPENSION · ORAL

Approval history

2025-09-23Labeling · Supplement 41 · standardLetterAP
2024-09-04Labeling · Supplement 42 · standardLetterAP
2019-01-04Labeling · Supplement 36 · standardLabelAP
2018-03-22Labeling · Supplement 35 · standardLabelAP
2017-11-17Labeling · Supplement 34 · standardLabelAP
2017-03-23Labeling · Supplement 31 · standardLetterAP
2014-07-03Labeling · Supplement 27 · unknownLetterAP
2014-06-06Labeling · Supplement 30 · standardLetterAP
2014-05-08Manufacturing (CMC) · Supplement 29 · standardAP
2014-02-28Manufacturing (CMC) · Supplement 28 · standardAP
2013-02-08Labeling · Supplement 23 · standardLetterAP
2011-10-30REMS · Supplement 25LetterAP
2011-03-03Labeling · Supplement 18 · standardLetterAP
2011-03-03Labeling · Supplement 22 · standardLabelAP
2011-03-03Labeling · Supplement 20 · standardLabelAP
2011-03-03Labeling · Supplement 19 · standardLetterAP
2011-03-03Labeling · Supplement 9 · standardLabelAP
2011-03-03Labeling · Supplement 15 · standardLetterAP
2011-03-03Labeling · Supplement 13 · standardLetterAP
2009-04-23Labeling · Supplement 21 · 901 requiredLetterAP
2007-08-31Labeling · Supplement 14 · standardLetterAP
2005-10-28Efficacy · Supplement 8 · priorityLabelAP
2005-03-25Labeling · Supplement 7 · standardLetterAP
2002-09-10Manufacturing (CMC) · Supplement 3 · standardAP
2002-04-01Labeling · Supplement 2 · standardLetterAP
2002-01-18Manufacturing (CMC) · Supplement 1 · standardAP
2001-05-25Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →